Medicare AdvantageCoverageLow impact
MA08.078e, Sebelipase alfa (Kanuma®)
Independence Blue Cross·Endocrinology, Gastroenterology, Pediatrics·Pharmacy
Effective date
Sep 3, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.078e for Sebelipase alfa (Kanuma®) has been reissued and will take effect on September 3, 2025. This pharmacy policy update may impact coverage criteria, prior authorization requirements, or billing procedures for this rare enzyme replacement therapy used to treat lysosomal acid lipase deficiency.
Action Required
By September 3, 2025: Billing team should review the full policy details at the provided URL to identify any changes to prior authorization requirements, coverage criteria, or billing procedures for Sebelipase alfa (Kanuma®). Update billing system and prior authorization workflows as needed based on the complete policy content.